Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window I think that ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to moderate ...
Paolo Ferrigno Product Manager prefilled syringes and cartridges Datwyler Healthcare ...
PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...
Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...
Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...
Enables convenient on-body delivery of higher dose therapies like anti-cancer treatments and monoclonal antibodiesUtilizes a pre-verified large-volume platform solution to speed time to marketMeets ...
Halozyme Therapeutics Inc. and Skye Bioscience Inc. have entered a non-exclusive global collaboration and license agreement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback